NCT03384654
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT03384654 ↗
- Completed
- Janssen Research & Development, LLC
- Standard
We haven't built an HCP commentary report on NCT03384654 (vincristine, doxorubicin and 7 more in Precursor Cell Lymphoblastic Leukemia-Lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03384654 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| YouTube | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- Daratumumab; Vincristine; Prednisone; Doxorubicin; Peg-asparaginase; Cyclophosphamide; Cytarabine; 6-mercaptopurine; Methotrexate
- Arms
- Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL · Experimental
- Cohort 2: T-Cell ALL/LL · Experimental
- Enrollment
- 47
- Primary outcomes
- Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)
- Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL
- Sponsor
- Janssen Research & Development, LLC
- Start
- May 14, 2018
- Primary completion
- Sep 22, 2022
- Results posted
- Yes
- Registry record
- NCT03384654 · updated May 25, 2025
Publications
linked from the registry- Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puyo P, Micalizzi C, Rossig C, Shukla N, Gilad G, Locatelli F, Baruchel A, Zwaan CM, Bezler NS, Rubio-San-Simon A, Taussig DC, Raetz EA, Mao ZJ, Wood BL, Alvarez Arias D, Krevvata M, Nnane I, Bandyopadhyay N, Lopez Solano L, Dennis RM, Carson R, Vora A. Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024 Nov 21;144(21):2237-2247. doi: 10.1182/blood.2024024493. PubMed 39158071
- Ruhayel SD, Valvi S. Daratumumab in T-cell acute lymphoblastic leukaemia: A case report and review of the literature. Pediatr Blood Cancer. 2021 May;68(5):e28829. doi: 10.1002/pbc.28829. Epub 2020 Nov 27. No abstract available. PubMed 33245179